Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
AJ Scheen - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
[HTML][HTML] EFFICACY OF LIRAGLUTIDE IN PEDIATRIC OBESITY: A REVIEW OF CLINICAL TRIAL DATA
M Agosta, M Sofia, S Pezzino, S D'Amato, G Litrico… - Obesity Medicine, 2024 - Elsevier
Pediatric obesity is steadily increasing, and reaching alarming levels; for this reason,
effective interventions are necessary to fight this global health challenge. First-line …
effective interventions are necessary to fight this global health challenge. First-line …
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study
M Jensterle, S Ferjan, A Janez - Frontiers in endocrinology, 2024 - frontiersin.org
Background Withdrawal of semaglutide is frequently followed by weight regain due to
compensatory biological changes that prevent the maintenance of long-term weight loss …
compensatory biological changes that prevent the maintenance of long-term weight loss …
GLP-1-Rezeptor-Agonisten bei Metformin-Therapie: Risiko für GI-Nebenwirkungen?
A Simon - Diabetologie und Stoffwechsel, 2024 - thieme-connect.com
Gastrointestinale (GI) Nebenwirkungen sind eine häufige Begleiterscheinung von
Antidiabetika und werden ua bei einer Therapie mit Metformin oder mit GLP-1-Rezeptor …
Antidiabetika und werden ua bei einer Therapie mit Metformin oder mit GLP-1-Rezeptor …